CourageAS Biotherapeutics
PrivateLast Round
Joint Venture
Feb 14, 2025
Company Overview
CourageAS Biotherapeutics is a biotechnology company that develops non-viral genome editing therapies for the treatment of Angelman syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CourageAS Biotherapeutics Comparables
Compare CourageAS Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MavriX Bio | 85% | |
| Biom Therapeutics | 84% | |
| GEMMA Biotherapeutics | 82% | |
CourageAS Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Joint Venture | Feb 14, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 14, 2025
Funded by Couragene and Foundation for Angelman Syndrome Therapeutics.
CourageAS Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CourageAS Biotherapeutics's valuation, stock price, and market status.